

Article

# Ru-Catalyzed Asymmetric Addition of Arylboronic Acids to Aliphatic Aldehydes via *P*-Chiral Monophosphorous Ligands

Rui Miao <sup>1,†</sup>, Yanping Xia <sup>1,†</sup>, Yifei Wei <sup>1</sup>, Lu Ouyang <sup>1,\*</sup> and Renshi Luo <sup>1,2,\*</sup>

<sup>1</sup> School of Pharmacy, Gannan Medical University, Ganzhou 341000, China; miaorui202205@163.com (R.M.); xyp110220@163.com (Y.X.); gnyxyghwyf@163.com (Y.W.)

<sup>2</sup> College of Chemistry and Environmental Engineering, Shaoguan University, Shaoguan 512005, China

\* Correspondence: oyl3074@163.com (L.O.); luorensi2010@163.com (R.L.)

† These authors contributed equally to this work.

**Abstract:** Chiral alcohols are among the most widely applied in fine chemicals, pharmaceuticals and agrochemicals. Herein, the Ru-monophosphine catalyst formed in situ was found to promote an enantioselective addition of aliphatic aldehydes with arylboronic acids, delivering the chiral alcohols in excellent yields and enantioselectivities and exhibiting a broad scope of aliphatic aldehydes and arylboronic acids. The enantioselectivities are highly dependent on the monophosphorous ligands. The utility of this asymmetric synthetic method was showcased by a large-scale transformation.

**Keywords:** Ru-catalyzed; asymmetric addition; *P*-chiral monophosphorous ligands; chiral alcohols



**Citation:** Miao, R.; Xia, Y.; Wei, Y.; Ouyang, L.; Luo, R. Ru-Catalyzed Asymmetric Addition of Arylboronic Acids to Aliphatic Aldehydes via *P*-Chiral Monophosphorous Ligands. *Molecules* **2022**, *27*, 3898. <https://doi.org/10.3390/molecules27123898>

Academic Editors: Zhanhui Yang and Daoshan Yang

Received: 17 May 2022

Accepted: 13 June 2022

Published: 17 June 2022

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Copyright:** © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

## 1. Introduction


Chiral alcohols are widely present in biologically active substances and pharmaceuticals [1–7]. Of these, chiral aryl alkyl alcohols are one important class of alcohols. The ubiquity of aryl alkyl alcohols as high-ranking intermediates makes them appealing precursors [8–10]. Thus, the invention of methods for the preparing of such chiral aryl alkyl alcohols features an important role in organic synthesis. Classic methods for constructing such chiral molecules include asymmetric hydrogenation of ketones [11–13], asymmetric hydrogen transfer reduction of ketones or unsaturated ketones [14–21], along with the asymmetric addition of organometallic reagents to aldehydes [22–24]. As an alternative, strategies via the asymmetric homologation reaction [25–28], tandem Michael–MPV reaction and subsequent reductive desulfurization [29], as well as the asymmetric addition of aldehydes with arylboronic acids were also established [30,31]. It is worth noting that the tandem  $\alpha$ -alkylation/asymmetric reactions of ketones with alcohols [32] and the asymmetric Guerbet reaction of alcohols [33,34] are green and high-efficient strategies.

Similar to the organometallic reagents, the addition of organoborons to carbonyl compounds allows for the generation of chiral alcohols in direct and effective ways. Compared with the disadvantages of organometallic reagents [22–24], the organoborons feature the advantages of easy manipulation, low toxicity and good functional group tolerance [35], which has attracted great attention [36–38] since Miyaura reported the first Rh-catalyzed asymmetric addition of arylboronic acid to aldehydes in 1998 [39]. For example, metals including Rh [40–48], Ru [49], Ni [50], Co [51] and Pd [52–54] have been intensively explored in this regard recently. Additionally, miscellaneous carbonyl compounds, such as asisatins [55–58], ketoesters [59–63], diketones [64–66], trifluoroacetophenones [67–69], inactive ketones [70–72] and aldehydes [73–75] were successfully employed to couple with organoborons reagents.

Despite the fact that these remarkable achievements were created in the asymmetric addition of carbonyl compounds with organoboron reagents, efforts have been mainly devoted to the active ketones [55–69], inactive ketones [70–72], and aromatic aldehydes [73–75],


but studies on aliphatic aldehydes have been less reported [30]. In this regard, the development of new, high-efficient catalytic systems for the enantioselective addition of aliphatic aldehydes with arylboronic acids still is desirable.

**L1~L8** (Scheme 1) represent one kind of phosphorus ligand featured with a *P*-chiral center, which is successfully utilized in asymmetric synthesis [76–82]. For example, the ligands **L3** and **L9** were discovered to realize the asymmetric addition of aromatic aldehydes and active ketones with arylboronic acids with excellent enantioselectivities [67,83]. Based on this, we envisioned to further extend the utility of these chiral phosphorous ligands in the asymmetric catalysis. Herein, we reported the Ru-catalyzed enantioselective addition of aliphatic aldehydes with arylboronic acids via *P*-chiral monophosphorous ligands to access chiral secondary alcohols (Scheme 2), delivering the desired aryl alkyl alcohols in excellent yields and enantioselectivities. The application for gram-scale synthesis of **3da** was also disclosed.



**Scheme 1.** Chiral phosphorous ligands developed by Tang's group.


**This work:**



**Scheme 2.** Asymmetric addition of aliphatic aldehydes with arylboronic acids.

## 2. Results and Discussions

At the outset of the research, initial experimental results show that the monophosphine ligand **L1** effectively promoted the Ru (II)-catalyzed asymmetric addition of phenylpropanal **1a** with 4-methylphenylboronic acid **2a** to access chiral alcohol **3aa** in excellent yields and with good enantioselectivity; only a trace amount of **4aa** was obtained as a byproduct (Table 1, entry 1). Further ligand investigations indicated that the ligands had a remarkable influence on enantioselectivity (Table 1, entries 2~5 and entry 11). For instance, good enantioselectivities can be afforded by using **L3** or **L5** as chiral phosphorous ligands (Table 1, entries 3 and 5), while a racemic or nearly racemic product was formed by employing **L2**, **L4** and **L11** (Table 1, entries 2, 4 and 11), indicating that the substituents on the carbon between the phosphorus and oxygen atom appear to have a negative influence on enantioselectivity.


**Table 1.** Ligand and precursor screening of metal-catalyzed asymmetric additions of aliphatic aldehydes <sup>a</sup>.


Entry	Metal	Ligands	Conv. (%) <sup>b</sup>	NMR Yield of 3aa/4aa (%) <sup>b</sup>	Isolated Yield of 3aa (%)	<i>er</i> of 3aa (%) <sup>c</sup>
1	[RuCl <sub>2</sub> (cymene)] <sub>2</sub>	L1	>99	97/4	92	89:11
2	[RuCl <sub>2</sub> (cymene)] <sub>2</sub>	L2	>99	91/4	80	50:50
3	[RuCl <sub>2</sub> (cymene)] <sub>2</sub>	L3	>99	93/3	83	83:17
4	[RuCl <sub>2</sub> (cymene)] <sub>2</sub>	L4	16	12/4	10	59:41
5	[RuCl <sub>2</sub> (cymene)] <sub>2</sub>	L5	78	64/4	54	83:17
6	[RuCl <sub>2</sub> (cymene)] <sub>2</sub>	L6	–	Trace	–	26:74
7	[RuCl <sub>2</sub> (cymene)] <sub>2</sub>	L7	53	29/3	12	30:70
8	[RuCl <sub>2</sub> (cymene)] <sub>2</sub>	L8	66	41/4	16	77:23
9	[RuCl <sub>2</sub> (cymene)] <sub>2</sub>	L9	69	39/2	18	61:39
10	[RuCl <sub>2</sub> (cymene)] <sub>2</sub>	L10	65	30/2	14	48:52
11	[RuCl <sub>2</sub> (cymene)] <sub>2</sub>	L11	70	36/3	14	57:43
12	[RuCl <sub>2</sub> (benzene)] <sub>2</sub>	L1	>99	94/5	86	89:11
13	[RuCl <sub>2</sub> Cp*] <sub>2</sub>	L1	>99	100/0	96	87:13
14	[Rh(CH <sub>2</sub> CH <sub>2</sub> ) <sub>2</sub> Cl] <sub>2</sub>	L1	>99	93/8	80	49:51
15	[Ir(coe) <sub>2</sub> Cl] <sub>2</sub>	L1	–	Trace	–	61:39

<sup>a</sup> Performed with **1a** (0.5 mmol), **2a** (2.0 eq.), metal (1 mol%), ligand (2 mol%), K<sub>2</sub>CO<sub>3</sub> (2.0 eq.), toluene (1.5 mL), H<sub>2</sub>O (0.5 mL), at 80 °C under N<sub>2</sub> atmosphere for 12 h. <sup>b</sup> Determined by NMR with dimethyl terephthalate as internal standard. <sup>c</sup> Determined by Chiral OJ-H column.

Similar trends were also observed by using chiral bisphosphine ligands **L6~L7** or **L9~L10**, which were connected via  $\alpha$ -position of a *P*-chiral center (Table 1, entries 6~7 and 9~10). For example, only low enantioselectivity was shown when bisphosphine ligands **L6~L7** and **L9~L10** were utilized in the reaction, while a moderate enantioselective product could be afforded by using **L8** as a bisphosphine ligand, which was coupled at the  $\beta$ -position (Table 1, entry 8). In general, the ruthenium precursors have no influence on the yields and enantioselectivities of this reaction (Table 1, entries 12 and 13). However, only low yields and enantioselectivities are accomplished using rhodium and iridium complexes as precursors (Table 1, entries 14 and 15).

The reaction was further assessed under various reaction conditions (Table 2). Solvent screening showcased that xylene/H<sub>2</sub>O was the optimal reaction medium, providing the corresponding asymmetric addition product **3aa** in full conversion and 91:9 *er* (Table 2, entry 7). Interestingly, full conversion and 93:7 *er* were obtained even when the reaction was conducted within 4 h (Table 2, entry 8). Corresponding various bases also delivered the desired chiral alcohol product **3aa** in good enantioselectivities (Table 2, entries 9~16), while organic bases, such as 1, 4-diazabicyclo [2.2.2] octane (DABCO), afforded a lower yield than inorganic bases (Table 2, entry 17).


**Table 2.** Optimization of reaction conditions <sup>a</sup>.


Entry	Solvent	Solvent	Conv. (%) <sup>b</sup>	NMR Yield of 3aa/4aa (%) <sup>b</sup>	Isolated Yield of 3aa (%)	er of 3aa (%) <sup>c</sup>
1	H <sub>2</sub> O	K <sub>2</sub> CO <sub>3</sub>	>99	91/4	90	86:14
2	toluene	K <sub>2</sub> CO <sub>3</sub>	>99	94/3	89	87:13
3	toluene/H <sub>2</sub> O (3:1)	K <sub>2</sub> CO <sub>3</sub>	>99	96/4	92	89:11
4	dioxane	K <sub>2</sub> CO <sub>3</sub>	>99	95/3	86	90:10
5	dioxane/H <sub>2</sub> O (3:1)	K <sub>2</sub> CO <sub>3</sub>	>99	92/2	76	89:11
6	MTBE/H <sub>2</sub> O (5:1)	K <sub>2</sub> CO <sub>3</sub>	>99	80/8	67	90:10
7	xylene/H <sub>2</sub> O (3:1)	K <sub>2</sub> CO <sub>3</sub>	>99	95/5	91	91:9
8 <sup>d</sup>	xylene/H <sub>2</sub> O (3:1)	K <sub>2</sub> CO <sub>3</sub>	>99	96/3	95	93:7
9	THF	K <sub>2</sub> CO <sub>3</sub>	85	64/4	53	76:24
10	xylene/H <sub>2</sub> O (3:1)	K <sub>3</sub> PO <sub>4</sub>	>99	93/4	90	89:11
11	xylene/H <sub>2</sub> O (3:1)	Na <sub>2</sub> CO <sub>3</sub>	>99	96/4	88	90:10
12	xylene/H <sub>2</sub> O (3:1)	Li <sub>2</sub> CO <sub>3</sub>	>99	95/5	82	90:10
13	xylene/H <sub>2</sub> O (3:1)	Cs <sub>2</sub> CO <sub>3</sub>	>99	96/5	80	89:11
14	xylene/H <sub>2</sub> O (3:1)	KOH	>99	87/3	91	89:11
15	xylene/H <sub>2</sub> O (3:1)	KOtBu	>99	80/3	55	92:8
16	xylene/H <sub>2</sub> O (3:1)	NaOMe	89	77/2	67	91:9
17	xylene/H <sub>2</sub> O (3:1)	DABCO	88	78/5	51	90:10

<sup>a</sup> Performed with **1a** (0.5 mmol), **2a** (2.0 eq.), [RuCl<sub>2</sub>(cymene)]<sub>2</sub> (1.0 mol%), **L1** (2 mol%), base (2.0 eq.), solvent (2.0 mL), at 80 °C under N<sub>2</sub> atmosphere for 12 h. <sup>b</sup> Determined by NMR with dimethyl terephthalate as internal standard. <sup>c</sup> Determined by Chiral OJ-H column. <sup>d</sup> reaction time: 4 h.


Having established the optimal conditions, we next investigated the scope of the reaction substrates (Scheme 3).

Generally, *para*-substituted arylboronic acids bearing electron-donating or electron-withdrawing groups (**2a**–**2h**) reacted with phenyl propanal (**1a**) smoothly to form the relevant alcohol products (**3aa**, **3ac** and **3ae**–**3ah**) in excellent yields and enantioselectivities. However, only moderate yields and good enantioselectivities were observed when arylboronic acids bearing alkoxy substituents in the *para* position were introduced (**3ab** and **3ad**). On the other hand, the position of the substituent on aryl boronic acid has significant influence on enantioselectivity and yield. For instance, arylboronic acids bearing substituents in the *ortho* position resulted in low yields and enantioselectivities (**3ai** and **3aj**), presumably due to *ortho* effects [83]. Gratifyingly, the *meta*-substituted phenylboronic acids are also well compatible under the standard conditions, giving the desired addition products excellent enantioselectivities and yields (**3ak**–**3am**). In addition, except for thiophene boronic acid (**3ao**), other different boronic acids, including 2-naphthalene boronic acid, phenyl boronic acid and disubstituted boronic acid, worked well in this catalytic system to yield the alcohols in excellent yields and enantioselectivities (**3an**, **3ap** and **3aq**). Unlike aryl boronic acid bearing alkoxy, phenyl propanal bearing 4-methoxy substituent on the phenyl group resulted in a low yield but with excellent enantioselectivities (**3ba** and **3be**). To our satisfaction, excellent yields and enantioselectivities resulted when furan-substituted propionaldehyde was loaded in this Ru-monophosphine catalytic system (**3ca** and **3ce**). Interestingly, aldehydes with electron-withdrawing substituents (**1j**) are also compatible with this catalytic system, giving desirable product **3ja** in the yield of 74% and 91:9 *er*.




**Scheme 3.** Substrates of 3-arylpropanal for asymmetric addition with arylboronic acids <sup>a,b</sup>. <sup>a</sup> Performed with 1 (0.5 mmol), 2 (2.0 eq.), [RuCl<sub>2</sub>(cymene)]<sub>2</sub> (1.0 mol%), L1 (2 mol%), K<sub>2</sub>CO<sub>3</sub> (2.0 eq.), xylene (1.5 mL) and H<sub>2</sub>O (0.5 mL), at 80 °C under N<sub>2</sub> atmosphere for 4 h. <sup>b</sup> The yield is isolated yield and *ee* is determined by CHIRAL column.

We next investigated the utility of this catalytic system for the substrate scope of aliphatic aldehydes bearing no aryl substituents (Scheme 4). Various common aliphatic aldehydes including cyclohexylformaldehyde, n-heptanal, isovaleraldehyde and propionaldehyde were also well tolerated in this catalytic system. Notably, the electron-withdrawing and electron-donating aryl boronic acids could be used as nucleophiles, generating chiral alcohols in 82%~93% yields and 93:7~95:5 *ers* (3da~3ge). Due to the steric hindrance, only a moderate yield and good enantioselectivity were afforded (3ha) when *t*-BuCHO was employed as a substrate under standard conditions. In addition, cinnamaldehyde can also react with 2a, giving 3ia in 90% *ee*.




**Scheme 4.** Substrates of alkyl aldehyde for asymmetric addition with arylboronic acids <sup>a,b</sup>.  
<sup>a</sup> Performed with **1** (0.5 mmol), **2** (2.0 eq.), [RuCl<sub>2</sub>(cymene)]<sub>2</sub> (1.0 mol%), **L1** (2 mol%), K<sub>2</sub>CO<sub>3</sub> (2.0 eq.), xylene (1.5 mL) and H<sub>2</sub>O (0.5 mL), at 80 °C under N<sub>2</sub> atmosphere for 4 h. <sup>b</sup> The yield is isolated yield and *ee* is determined by CHIRAL column.

Additionally, in order to gain more insight into the versatility of nucleophilic reagents, other organoboron reagents were utilized under standard conditions. To our delight, potassium trifluoro(phenyl)borate (**2s**) could be compatible with this catalytic system, providing the desirable product in a moderate yield and with good *ee*. However, no desired product **3ar** was afforded when 4,4,5,5-tetramethyl-2-phenyl-1,3,2-dioxaborolane (**2r**) was severed as an organoboron reagent in this system (Scheme 5).




**Scheme 5.** Substrates and other organoboron reagents tested in the system.

In order to illustrate the practicability of the catalytic system, we carried out a large-scale reaction of cyclohexyl formaldehyde (**1d**) and *p*-methylphenyl boronic acid (**2a**). Indeed, the corresponding addition product **3da** was successfully afforded on a 6.0 mmol scale from **1d** in a 91% yield and 94:6 *er* (Scheme 6).




**Scheme 6.** Large-scale experiment.

The model reaction was measured over time to know about details of this reaction (Scheme 7). To our surprise, the treatment of **1a** with **2a** under standard conditions within 4 min afforded the desirable alcohol product **3aa** in the yield of 96% and 92:8 *er*, albeit with trace amounts of a ketone byproduct. The best enantioselectivity of product **3aa** was observed in 4 h, after which the enantioselectivities of alcohol decreased slightly, and the byproduct ketone increased slightly as time went by. In addition, the racemization of enantioenriched product **3aa** was monitored over time under the standard system, which showcased that the yield of **4aa** increased gradually, and a slight loss of enantioselectivity was observed (Scheme 8).




**Scheme 7.** Plots for relationship of time, yield and enantioselectivity.



**Scheme 8.** Plots for relationship of time, enantioselectivity and ketone formation.

Based on the experimental results, we proposed a possible mechanistic cycle described in Scheme 9 [84]. Firstly, the catalyst **Ru-L1** was generated in situ with an Ru precursor and **L1**, followed by a transmetalation with aryl boronic acid to form **Int-I** under the condition of base. Subsequently, there was the coordination of aliphatic aldehydes with **Int-I** to generate the **Int-II**, followed by carbonyl insertion to produce **Int-III**. The  $\beta$ -H elimination

of **Int-III** produced byproduct **4**. Finally, the addition of product **3** was released, and the catalyst was regenerated under the action of water and aryl boronic acid.



**Scheme 9.** Proposed mechanism.

In summary, we described a Ru-catalyzed asymmetric addition of aliphatic aldehydes with aryl boronic acids based on a monophosphorous ligand, providing the corresponding alcohol products in excellent yields and enantioselectivities. A large-scale experiment showcased the utility of this catalytic system, which provides a supplementary method on acquiring chiral aryl alkyl alcohols.

### 3. Materials and Methods

#### 3.1. General Information

Aliphatic aldehyde, arylboronic acids, dioxane, H<sub>2</sub>O, MTBE, THF, xylene and toluene were commercially acquired and used directly without further purifications. Reactions were carried out under a nitrogen atmosphere. <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded using a 400 MHz NMR spectrometer (CDCl<sub>3</sub>, δ<sub>H</sub> = 7.26 ppm, δ<sub>C</sub> = 77.23 ppm). The melting point was determined by a WRR melting point apparatus. The progress of the reaction was monitored by thin layer chromatography (TLC) or Agilent GC-7900. HPLC analyses were performed with an Agilent 1100 instrument using Chiralcel OD-H or OJ-H or Chiralpak AD-H, AS-H, IA or IB columns (0.46 cm diameter × 25 cm length). Optical rotations and MS spectra were recorded on a Perkin Elmer polarimeter (Model 341) and an ESI-ion trap mass spectrometer (Shimadzu LCMS-IT-TOF) separately.

#### 3.2. General Procedure for Asymmetric Addition of Aliphatic Aldehydes

A mixture of aliphatic aldehydes (0.5 mmol), boric acids (1.0 mmol, 2.0 equiv), [RuCl<sub>2</sub>(cymene)]<sub>2</sub> (3.1 mg, 1.0 mol%), **L1** (3.3 mg, 2.0 mol%) and K<sub>2</sub>CO<sub>3</sub> (138.2 mg, 2.0 equiv) in *p*-xylene (1.5 mL)/H<sub>2</sub>O (0.5 mL) was added to a 25.0 mL Schlenk tube successively. Then, the reaction was stirred at 80 °C under N<sub>2</sub> for 4h after which the reaction was diluted with H<sub>2</sub>O (15.0 mL), neutralized with HCl, and extracted with EtOAc (10.0 mL × 3). The organic layer was washed with brine (10.0 mL × 3) and dried over anhydrous MgSO<sub>4</sub> after removal of the solvent under vacuum to afford the crude product, which was purified by column chromatography on silica gel with hexanes or petroleum ether/ethyl acetate (5:1 to 20:1) to deliver the desired product **3**. The enantioselectivities were determined by OD-H, AD-H, OJ-H, AS-H, IA or IB columns.

*3-phenyl-1-(p-tolyl)propan-1-ol (3aa)* [85]

[α]<sub>D</sub><sup>20</sup> = +17.5 (c 0.29, CH<sub>2</sub>Cl<sub>2</sub>). Yield: 93% (105.1 mg) as yellow solid; m.p. 48–53 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.66–6.66 (m, 9H), 4.60 (dd, *J* = 7.7, 5.5, 1H), 2.94–2.49 (m, 2H),



2.32 (s, 3H) and 2.21–1.86 (m, 3H).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  141.94, 141.67, 137.33, 129.24, 128.51, 128.43, 125.98, 125.87, 73.75, 40.42, 32.15 and 21.18. The enantiomeric excess was determined by HPLC using Daicel Chiralpak OJ-H column, hexane/*i*-PrOH 95:5, flow rate 1.0 mL/min, UV detection at 220 nm,  $t_{\text{minor}} = 13.758$  min,  $t_{\text{major}} = 16.774$  min, and 93:7 *er*.

1-(4-methoxyphenyl)-3-phenylpropan-1-ol (**3ab**) [85]

$[\alpha]_{\text{D}}^{20} = +19.3$  (c 0.66,  $\text{CH}_2\text{Cl}_2$ ). Yield: 55% (66.6 mg) as a yellow oil;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.35–7.08 (m, 7H), 6.86 (d,  $J = 8.3$ , 2H), 4.59 (dd,  $J = 6.7$ , 1H), 3.77 (s, 3H), 2.78–2.51 (m, 2H) and 2.19–1.89 (m, 3H).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  159.11, 141.91, 136.77, 128.49, 128.42, 127.27, 125.87, 113.92, 73.49, 55.32, 40.39 and 32.16. The enantiomeric excess was determined by HPLC using Daicel Chiralpak AD-H column, hexane/*i*-PrOH 95:5, flow rate 1.0 mL/min, UV detection at 220 nm,  $t_{\text{minor}} = 19.320$  min,  $t_{\text{major}} = 21.773$  min and 88:12 *er*.

1-(4-(*tert*-butyl)phenyl)-3-phenylpropan-1-ol (**3ac**) [86]

$[\alpha]_{\text{D}}^{20} = +10.5$  (c 0.32,  $\text{CH}_2\text{Cl}_2$ ). Yield: 97% (130.2 mg) as a yellow oil;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.54–6.94 (m, 9H), 4.63 (dd,  $J = 7.9$ , 5.4, 1H), 2.99–2.54 (m, 2H), 2.25–1.98 (m, 2H), 1.95 (s, 1H) and 1.31 (s, 9H).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  150.64, 141.94, 141.62, 128.50, 128.41, 125.85, 125.74, 125.46, 73.71, 40.32, 34.58, 32.18 and 31.42. The enantiomeric excess was determined by HPLC using Daicel Chiralpak OJ-H column, hexane/*i*-PrOH 95:5, flow rate 1.0 mL/min, UV detection at 220 nm,  $t_{\text{minor}} = 10.092$  min,  $t_{\text{major}} = 14.461$  min and 93:7 *er*.

1-(4-isopropoxyphenyl)-3-phenylpropan-1-ol (**3ad**)

$[\alpha]_{\text{D}}^{20} = +12.1$  (c 0.22,  $\text{CH}_2\text{Cl}_2$ ). Yield: 45% (60.7 mg) as a yellow oil;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.53–7.03 (m, 7H), 6.86 (d,  $J = 8.3$ , 2H), 4.61 (dd,  $J = 6.7$ , 1H), 4.53 (p,  $J = 6.0$ , 1H), 2.78–2.57 (m, 2H), 2.19–1.93 (m, 2H), 1.87 (s, 1H) and 1.33 (d,  $J = 6.0$ , 6H).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  157.45, 141.90, 136.51, 128.47, 128.39, 127.25, 125.83, 115.86, 73.55, 69.95, 40.32, 32.17 and 22.09. HRMS-ESI ( $m/z$ ): calculated for  $\text{C}_{18}\text{H}_{23}\text{O}_2$ ,  $[\text{M}+\text{H}]$ : 271.1698, found 271.1701. The enantiomeric excess was determined by HPLC using Daicel Chiralpak AD-H column, hexane/*i*-PrOH 95:5, flow rate 1.0 mL/min, UV detection at 220 nm,  $t_{\text{minor}} = 14.219$  min,  $t_{\text{major}} = 16.039$  min and 88:12 *er*.

1-(4-chlorophenyl)-3-phenylpropan-1-ol (**3ae**) [87]

$[\alpha]_{\text{D}}^{20} = +13.1$  (c 1.17,  $\text{CH}_2\text{Cl}_2$ ). Yield: 96% (118.3 mg) as a yellow oil;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.53–6.94 (m, 9H), 4.60 (dd,  $J = 7.8$ , 5.3, 1H), 2.81–2.52 (m, 2H), 2.15 (s, 1H) and 2.12–1.88 (m, 2H).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  143.06, 141.54, 133.26, 128.67, 128.50, 128.46, 127.37, 126.02, 73.15, 40.51 and 31.95. The enantiomeric excess was determined by HPLC using Daicel Chiralpak IB column, hexane/*i*-PrOH 95:5, flow rate 0.5 mL/min, UV detection at 220 nm,  $t_{\text{minor}} = 20.451$  min,  $t_{\text{major}} = 23.591$  min and 92:8 *er*.

1-(4-bromophenyl)-3-phenylpropan-1-ol (**3af**) [88]

$[\alpha]_{\text{D}}^{20} = +10.0$  (c 1.31,  $\text{CH}_2\text{Cl}_2$ ). Yield: 91% (132.4 mg) as a yellow oil;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.44 (d,  $J = 7.9$ , 2H), 7.35–7.03 (m, 7H), 4.59 (dd,  $J = 6.6$ , 1H), 2.75–2.56 (m, 2H), 2.12 (s, 1H) and 2.08–1.89 (m, 2H).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  143.58, 141.51, 131.62, 128.50, 128.46, 127.71, 126.02, 121.37, 73.18, 40.47 and 31.93. The enantiomeric excess was determined by HPLC using Daicel Chiralpak IB column, hexane/*i*-PrOH 95:5, flow rate 0.5 mL/min, UV detection at 220 nm,  $t_{\text{minor}} = 22.304$  min,  $t_{\text{major}} = 25.606$  min and 92:8 *er*.

1-(4-fluorophenyl)-3-phenylpropan-1-ol (**3ag**) [33]

$[\alpha]_{\text{D}}^{20} = +22.1$  (c 0.99,  $\text{CH}_2\text{Cl}_2$ ). Yield: 86% (98.8 mg) as a yellowish oil;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.60–7.09 (m, 7H), 7.01 (t,  $J = 8.6$ , 2H), 4.63 (dd,  $J = 7.8$ , 5.4, 1H), 2.77–2.57 (m, 2H) and 2.16–1.90 (m, 3H).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  162.24 (d,  $J = 245.4$ ), 141.61, 140.33 (d,  $J = 3.1$ ), 128.47, 128.44, 127.60 (d,  $J = 8.0$ ), 125.97, 115.33 (d,  $J = 21.3$ ), 73.22, 40.57 and 32.02. The enantiomeric excess was determined by HPLC using Daicel Chiralpak IB column, hexane/*i*-PrOH 95:5, flow rate 0.5 mL/min, UV detection at 220 nm,  $t_{\text{minor}} = 20.004$  min,  $t_{\text{major}} = 22.949$  min and 92:8 *er*.

3-phenyl-1-(4-(trifluoromethyl)phenyl)propan-1-ol (**3ah**) [33]

$[\alpha]_{\text{D}}^{20} = +17.1$  (c 1.32,  $\text{CH}_2\text{Cl}_2$ ). Yield: 94% (131.9 mg) as a yellow oil;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.56 (d,  $J = 8.0$ , 2H), 7.39 (d,  $J = 8.0$ , 2H), 7.34–6.99 (m, 5H), 4.68 (dd,  $J = 7.9$ , 5.2,

1H), 2.77–2.57 (m, 2H), 2.36 (s, 1H) and 2.13–1.91 (m, 2H).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  148.58, 141.38, 129.78 (q,  $J = 32.3$ ), 128.54, 128.45, 126.21, 126.09, 125.46 (q,  $J = 3.8$ ), 124.32 (q,  $J = 272.0$ ), 73.17, 40.56 and 31.86. The enantiomeric excess was determined by HPLC using Daicel Chiralpak IB column, hexane/*i*-PrOH 95:5, flow rate 0.5 mL/min, UV detection at 210 nm,  $t_{\text{minor}} = 21.798$  min,  $t_{\text{major}} = 24.446$  min and 93:7 *er*.

1-(2-fluorophenyl)-3-phenylpropan-1-ol (**3ai**) [33]

$[\alpha]_{\text{D}}^{20} = +20.8$  (c 0.53,  $\text{CH}_2\text{Cl}_2$ ). Yield: 49% (52.7 mg) as a yellow oil;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.45 (t,  $J = 7.6$ , 1H), 7.39–6.89 (m, 8H), 5.01 (t,  $J = 6.5$ , 1H), 2.90–2.58 (m, 2H) and 2.19–1.98 (m, 3H).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  159.87 (d,  $J = 245.5$ ), 141.64, 131.50 (d,  $J = 13.2$ ), 128.93 (d,  $J = 8.3$ ), 128.44, 128.43, 127.34 (d,  $J = 4.7$ ), 125.92, 124.35 (d,  $J = 3.6$ ), 115.37 (d,  $J = 21.9$ ), 68.01 (d,  $J = 2.5$ ), 39.42 and 32.02. The enantiomeric excess was determined by HPLC using Daicel Chiralpak IB column, hexane/*i*-PrOH 95:5, flow rate 0.5 mL/min, UV detection at 220 nm,  $t_{\text{minor}} = 17.583$  min,  $t_{\text{major}} = 19.992$  min and 84:16 *er*.

1-(2-methoxyphenyl)-3-phenylpropan-1-ol (**3aj**) [89]

$[\alpha]_{\text{D}}^{20} = +18.5$  (c 0.19,  $\text{CH}_2\text{Cl}_2$ ). Yield: 16% (19.4 mg) as a yellow oil;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.38–7.11 (m, 7H), 6.96 (t,  $J = 7.4$ , 1H), 6.88 (d,  $J = 8.2$ , 1H), 4.88 (dd,  $J = 8.0$ , 5.1, 1H), 3.84 (s, 3H), 2.89–2.57 (m, 3H) and 2.22–2.02 (m, 2H).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  156.65, 142.20, 132.27, 128.48, 128.39, 128.31, 127.02, 125.72, 120.80, 110.58, 70.71, 55.27, 38.68 and 32.38. The enantiomeric excess was determined by HPLC using Daicel Chiralpak IB column, hexane/*i*-PrOH 95:5, flow rate 0.5 mL/min, UV detection at 220 nm,  $t_{\text{minor}} = 19.673$  min,  $t_{\text{major}} = 24.260$  min and 74:26 *er*.

1-(3-chlorophenyl)-3-phenylpropan-1-ol (**3ak**) [88]

$[\alpha]_{\text{D}}^{20} = +15.0$  (c 0.55,  $\text{CH}_2\text{Cl}_2$ ). Yield: 91% (111.7 mg) as a yellow oil;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.46–6.98 (m, 9H), 4.59 (dd,  $J = 7.9$ , 5.2, 1H), 2.85–2.53 (m, 2H), 2.26 (s, 1H) and 2.10–1.90 (m, 2H).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  146.74, 141.51, 134.43, 129.83, 128.51, 128.48, 127.73, 126.17, 126.03, 124.11, 73.20, 40.48, 31.94. The enantiomeric excess was determined by HPLC using Daicel Chiralpak IB column, hexane/*i*-PrOH 95:5, flow rate 0.5 mL/min, UV detection at 220 nm,  $t_{\text{minor}} = 21.487$  min,  $t_{\text{major}} = 27.495$  min and 93:7 *er*.

3-phenyl-1-(*m*-tolyl)propan-1-ol (**3al**) [88]

$[\alpha]_{\text{D}}^{20} = +21.0$  (c 0.98,  $\text{CH}_2\text{Cl}_2$ ). Yield: 87% (98.3 mg) as a yellow oil;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.63–6.82 (m, 9H), 4.59 (dd,  $J = 7.8$ , 5.5, 1H), 2.84–2.53 (m, 2H), 2.33 (s, 3H) and 2.18–1.91 (m, 3H).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  144.64, 141.93, 138.19, 128.52, 128.47, 128.44, 128.42, 126.70, 125.89, 123.08, 73.94, 40.47, 32.17 and 21.53. The enantiomeric excess was determined by HPLC using Daicel Chiralpak IB column, hexane/*i*-PrOH 95:5, flow rate 0.5 mL/min, UV detection at 220 nm,  $t_{\text{minor}} = 17.873$  min,  $t_{\text{major}} = 20.271$  min and 92:8 *er*.

1-(3-isopropylphenyl)-3-phenylpropan-1-ol (**3am**)

$[\alpha]_{\text{D}}^{20} = +18.3$  (c 1.14,  $\text{CH}_2\text{Cl}_2$ ). Yield: 91% (102.8 mg) as a yellow oil;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.35–7.02 (m, 9H), 4.62 (dd,  $J = 7.9$ , 5.3, 1H), 2.89 (hept,  $J = 6.9$ , 1H), 2.80–2.59 (m, 2H), 2.16–1.88 (m, 3H) and 1.24 (d,  $J = 7.0$ , 6H).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  149.23, 144.65, 141.96, 128.55, 128.45, 125.90, 125.77, 124.17, 123.47, 74.11, 40.51, 34.24, 32.23 and 24.12 (d,  $J = 3.0$ ). HRMS-ESI ( $m/z$ ): calculated for  $\text{C}_{18}\text{H}_{22}\text{NaO}$ ,  $[\text{M}+\text{Na}]$ : 277.1568, found 277.1574. The enantiomeric excess was determined by HPLC using Daicel Chiralpak IB column, hexane/*i*-PrOH 95:5, flow rate 0.5 mL/min, UV detection at 220 nm,  $t_{\text{minor}} = 13.494$  min,  $t_{\text{major}} = 16.836$  min and 92:8 *er*.

1-(naphthalen-2-yl)-3-phenylpropan-1-ol (**3an**) [90]

$[\alpha]_{\text{D}}^{20} = +13.3$  (c 1.31,  $\text{CH}_2\text{Cl}_2$ ). Yield: 99% (130.2 mg) as a light-yellow solid; m.p. 81–83 °C;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.86–7.62 (m, 4H), 7.42 (dd,  $J = 12.0$ , 7.9, 3H), 7.23 (d,  $J = 7.1$ , 2H), 7.14 (d,  $J = 8.0$ , 3H), 4.74 (t,  $J = 6.6$ , 1H), 2.82–2.48 (m, 2H), 2.30 (s, 1H) and 2.22–1.98 (m, 2H).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  141.99, 141.86, 133.36, 133.10, 128.56, 128.50, 128.44, 128.04, 127.80, 126.26, 125.97, 125.95, 124.79, 124.17, 74.00, 40.38 and 32.12. The enantiomeric excess was determined by HPLC using Daicel Chiralpak OD-H column, hexane/*i*-PrOH 90:10, flow rate 1.0 mL/min, UV detection at 220 nm,  $t_{\text{minor}} = 18.230$  min,  $t_{\text{major}} = 23.050$  min and 92:8 *er*.

3-phenyl-1-(thiophen-2-yl)propan-1-ol (**3ao**) [91]

$[a]_D^{20} = +17.2$  (c 0.30, CH<sub>2</sub>Cl<sub>2</sub>). Yield: 38% (38.4 mg) as a colorless oil; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.38–7.12 (m, 6H), 6.97 (d, *J* = 5.3, 2H), 4.92 (t, *J* = 6.7, 1H), 2.83–2.64 (m, 2H), 2.40–2.11 (m, 2H) and 2.05 (s, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 148.53, 141.47, 128.52, 128.47, 126.70, 125.99, 124.72, 123.96, 69.54, 40.72 and 32.03. The enantiomeric excess was determined by HPLC using Daicel Chiralpak OD-H column, hexane/*i*-PrOH 95:5, flow rate 1.0 mL/min, UV detection at 220 nm, *t*<sub>minor</sub> = 21.015 min, *t*<sub>major</sub> = 31.268 min and 83:17 *er*.

**1,3-diphenylpropan-1-ol (3ap) [85]**

$[a]_D^{20} = +21.3$  (c 0.29, CH<sub>2</sub>Cl<sub>2</sub>). Yield: 85% (90.2 mg) as a yellow solid; m.p. 41–42 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.52–6.98 (m, 10H), 4.64 (dd, *J* = 7.8, 5.5, 1H), 2.87–2.46 (m, 2H) and 2.18–1.94 (m, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 144.62, 141.85, 128.56, 128.50, 128.45, 127.68, 126.00, 125.91, 73.90, 40.50 and 32.10. The enantiomeric excess was determined by HPLC using Daicel Chiralpak OJ-H column, hexane/*i*-PrOH 95:5, flow rate 1.0 mL/min, UV detection at 220 nm, *t*<sub>minor</sub> = 16.095 min, *t*<sub>major</sub> = 19.016 min and 93:7 *er*.

**1-(3-chloro-4-fluorophenyl)-3-phenylpropan-1-ol (3aq)**

$[a]_D^{20} = +15.2$  (c 1.10, CH<sub>2</sub>Cl<sub>2</sub>). Yield: 83% (110.2 mg) as a yellow oil; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.72–6.90 (m, 8H), 4.60 (dd, *J* = 7.9, 5.2, 1H), 2.77–2.58 (m, 2H), 2.12 (s, 1H) and 2.12–1.88 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 157.40 (d, *J* = 248.3), 141.70 (d, *J* = 3.7), 141.31, 128.53, 128.43, 128.18, 126.08, 125.62 (d, *J* = 7.2), 121.00 (d, *J* = 17.8), 116.54 (d, *J* = 21.1), 72.66, 40.56 and 31.89. HRMS-ESI (*m/z*): calculated for C<sub>15</sub>H<sub>15</sub>ClFO, [M+H]: 265.0795, found 265.0791. The enantiomeric excess was determined by HPLC using Daicel Chiralpak IB column, hexane/*i*-PrOH 95:5, flow rate 0.5 mL/min, UV detection at 220 nm, *t*<sub>minor</sub> = 23.081 min, *t*<sub>major</sub> = 26.696 min and 92:8 *er*.

**3-(4-methoxyphenyl)-1-(*p*-tolyl)propan-1-ol (3ba) [92]**

$[a]_D^{20} = +15.0$  (c 0.28, CH<sub>2</sub>Cl<sub>2</sub>). Yield: 23% (29.5 mg) as a colorless oil; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.48–6.97 (m, 6H), 6.82 (d, 2H), 4.63 (t, *J* = 6.7, 1H), 3.78 (s, 3H), 2.74–2.54 (m, 2H), 2.34 (s, 3H), 2.18–1.95 (m, 2H) and 1.80 (s, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 157.79, 141.65, 137.32, 133.88, 129.33, 129.20, 125.92, 113.81, 73.72, 55.27, 40.60, 31.18 and 21.13. The enantiomeric excess was determined by HPLC using Daicel Chiralpak IA column, hexane/*i*-PrOH 95:5, flow rate 1.0 mL/min, UV detection at 220 nm, *t*<sub>minor</sub> = 14.914 min, *t*<sub>major</sub> = 16.938 min and 93:7 *er*.

**1-(4-chlorophenyl)-3-(4-methoxyphenyl)propan-1-ol (3be) [92]**

$[a]_D^{20} = +6.9$  (c 0.49, CH<sub>2</sub>Cl<sub>2</sub>). Yield: 36% (49.8 mg) as a colorless oil; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.29 (q, *J* = 8.3, 4H), 7.09 (d, *J* = 8.2, 2H), 6.82 (d, *J* = 8.3, 2H), 4.64 (dd, *J* = 7.9, 5.3, 1H), 3.78 (s, 3H), 2.75–2.54 (m, 2H) and 2.12–1.88 (m, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 157.87, 143.11, 133.51, 133.21, 129.32, 128.63, 127.32, 113.89, 73.13, 55.28, 40.74 and 31.01. The enantiomeric excess was determined by HPLC using Daicel Chiralpak IA column, hexane/*i*-PrOH 95:5, flow rate 0.5 mL/min, UV detection at 220 nm, *t*<sub>minor</sub> = 30.043 min, *t*<sub>major</sub> = 32.492 min and 92:8 *er*.

**3-(5-methylfuran-2-yl)-1-(*p*-tolyl)propan-1-ol (3ca)**

$[a]_D^{20} = +14.4$  (c 1.02, CH<sub>2</sub>Cl<sub>2</sub>). Yield: 89% (102.3 mg) as a yellow oil; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.29–7.09 (m, 4H), 5.83 (d, *J* = 5.1, 2H), 4.64 (t, *J* = 6.7, 1H), 2.63 (h, *J* = 8.6, 8.1, 2H), 2.33 (s, 3H), 2.23 (s, 3H) and 2.12–1.94 (m, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 153.78, 150.39, 141.48, 137.30, 129.19, 125.92, 105.86, 105.60, 73.62, 37.24, 24.56, 21.15 and 13.54. HRMS-ESI (*m/z*): calculated for C<sub>15</sub>H<sub>19</sub>O<sub>2</sub>, [M + H]: 231.1385, found 231.1385. The enantiomeric excess was determined by HPLC using Daicel Chiralpak IB column, hexane/*i*-PrOH 95:5, flow rate 0.5 mL/min, UV detection at 220 nm, *t*<sub>minor</sub> = 13.845 min, *t*<sub>major</sub> = 14.888 min and 93:7 *er*.

**1-(4-chlorophenyl)-3-(5-methylfuran-2-yl)propan-1-ol (3ce)**

$[a]_D^{20} = +9.4$  (c 1.19, CH<sub>2</sub>Cl<sub>2</sub>). Yield: 95% (118.9 mg) as a yellow oil; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.26 (q, *J* = 8.4, 4H), 5.84 (d, *J* = 3.5, 2H), 4.65 (dd, *J* = 7.7, 5.5, 1H), 2.62 (t, *J* = 7.7, 2H), 2.28 (s, 1H), 2.23 (s, 3H) and 2.10–1.90 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 153.36, 150.53, 142.87, 133.22, 128.62, 127.31, 105.91, 105.81, 73.02, 37.36, 24.37 and 13.53. HRMS-ESI (*m/z*): calculated for C<sub>14</sub>H<sub>16</sub>ClO<sub>2</sub>, [M + H]: 251.0839, found 251.0836. The enantiomeric excess was determined by HPLC using Daicel Chiralpak OD-H column, hexane/*i*-PrOH

95:5, flow rate 1.0 mL/min, UV detection at 220 nm,  $t_{minor}$  = 17.860 min,  $t_{major}$  = 19.360 min and 94:6 *er*.

**3-(4-fluorophenyl)-1-(*p*-tolyl)propan-1-ol (3ja)**

$[a]_D^{20}$  = +20.4 (*c* 0.86, CH<sub>2</sub>Cl<sub>2</sub>). Yield: 74% (90.5 mg) as a yellow oil; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.24–7.05 (m, 6H), 6.93 (t, *J* = 8.8, 2H), 4.63–4.55 (m, 1H), 2.74–2.53 (m, 2H), 2.33 (s, 3H), 2.13–2.00 (m, 2H) and 1.94 (ddt, *J* = 13.6, 9.8, 6.0, 1H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  161.28 (d, *J* = 243.3), 141.53, 137.48 (d, *J* = 3.1), 137.43, 129.78 (d, *J* = 7.7), 129.26, 125.92, 115.10 (d, *J* = 21.1), 73.61, 40.50, 31.29 and 21.16. The enantiomeric excess was determined by HPLC using Daicel Chiralpak OJ-H column, hexane/*i*-PrOH 95:5, flow rate 1.0 mL/min, UV detection at 220 nm,  $t_{minor}$  = 14.161 min,  $t_{major}$  = 17.151 min and 91:9 *er*. HRMS-ESI (*m/z*): calcd for C<sub>16</sub>H<sub>18</sub>O, [M+H]: 245.1342, found 245.1335.

**cyclohexyl(*p*-tolyl)methanol (3da) [93]**

$[a]_D^{20}$  = +27.8 (*c* 0.93, CH<sub>2</sub>Cl<sub>2</sub>). Yield: 92% (93.9 mg) as a light-yellow oil; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.15 (q, *J* = 7.9, 4H), 4.30 (d, *J* = 7.3, 1H), 2.33 (s, 3H), 1.99 (d, *J* = 12.9, 1H), 1.87 (s, 1H), 1.75 (d, *J* = 12.9, 1H), 1.70–1.52 (m, 3H), 1.35 (d, *J* = 12.8, 1H) and 1.24–0.85 (m, 5H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  140.71, 137.02, 128.89, 126.60, 79.26, 44.93, 29.33, 28.98, 26.47, 26.13, 26.05 and 21.14. The enantiomeric excess was determined by HPLC using Daicel Chiralpak IB column, hexane/*i*-PrOH 95:5, flow rate 0.5 mL/min, UV detection at 220 nm,  $t_{minor}$  = 9.882 min,  $t_{major}$  = 10.925 min and 95:5 *er*.

**(4-chlorophenyl)(cyclohexyl)methanol (3de) [93]**

$[a]_D^{20}$  = +21.9 (*c* 0.96, CH<sub>2</sub>Cl<sub>2</sub>). Yield: 87% (97.7 mg) as a yellow oil; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.44–7.09 (m, 4H), 4.33 (d, *J* = 7.0, 1H), 2.03 (s, 1H), 1.91 (d, *J* = 12.9, 1H), 1.82–1.47 (m, 4H), 1.36 (d, *J* = 12.6, 1H) and 1.29–0.85 (m, 5H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  142.03, 132.99, 128.29, 127.99, 78.61, 45.00, 29.19, 28.65, 26.37, 26.05 and 25.97. The enantiomeric excess was determined by HPLC using Daicel Chiralpak IA column, hexane/*i*-PrOH 98:2, flow rate 0.5 mL/min, UV detection at 220 nm,  $t_{minor}$  = 25.489 min,  $t_{major}$  = 27.163 min and 95:5 *er*.

**cyclohexyl(4-(trifluoromethyl)phenyl)methanol (3dh) [94]**

$[a]_D^{20}$  = +16.5 (*c* 1.06, CH<sub>2</sub>Cl<sub>2</sub>). Yield: 83% (107.1 mg) as a white solid; m.p. 55–57 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.49 (dd, *J* = 73.7, 8.0, 4H), 4.44 (d, *J* = 6.7, 1H), 2.09 (s, 1H), 1.88 (d, *J* = 12.4, 1H), 1.81–1.53 (m, 4H), 1.39 (d, *J* = 12.6, 1H) and 1.27–0.93 (m, 5H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  147.51, 129.54 (q, *J* = 32.3), 126.90, 125.08 (q, *J* = 3.9), 124.22 (q, *J* = 271.9), 78.63, 45.03, 29.22, 28.36, 26.31, 26.04 and 25.94. The enantiomeric excess was determined by HPLC using Daicel Chiralpak IA column, hexane/*i*-PrOH 98:2, flow rate 0.5 mL/min, UV detection at 220 nm,  $t_{minor}$  = 21.107 min,  $t_{major}$  = 23.564 min and 93:7 *er*.

**1-(*p*-tolyl)heptan-1-ol (3ea) [92]**

$[a]_D^{20}$  = +21.7 (*c* 0.95, CH<sub>2</sub>Cl<sub>2</sub>). Yield: 93% (95.7 mg) as a yellow solid; m.p. 34–35 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.44–6.94 (m, 4H), 4.57 (t, *J* = 6.7, 1H), 2.33 (s, 3H), 2.04 (s, 1H), 1.83–1.59 (m, 2H), 1.43–1.15 (m, 8H) and 0.86 (t, *J* = 6.6, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  142.07, 137.07, 129.10, 125.91, 74.53, 39.07, 31.82, 29.26, 25.88, 22.66, 21.13 and 14.11. The enantiomeric excess was determined by HPLC using Daicel Chiralpak AS-H-column, hexane/*i*-PrOH 99:1, flow rate 1.0 mL/min, UV detection at 220 nm,  $t_{minor}$  = 8.920 min,  $t_{major}$  = 11.107 min and 93:7 *er*.

**1-(4-chlorophenyl)heptan-1-ol (3ee) [95]**

$[a]_D^{20}$  = +21.1 (*c* 0.97, CH<sub>2</sub>Cl<sub>2</sub>). Yield: 86% (97.4 mg) as a yellow solid; m.p. 50–52 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.47–7.12 (m, 4H), 4.61 (t, *J* = 6.7, 1H), 2.13 (s, 1H), 1.81–1.57 (m, 2H), 1.42–1.15 (m, 8H) and 0.87 (t, *J* = 6.7, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  143.39, 133.04, 128.53, 127.30, 73.97, 39.16, 31.76, 29.16, 25.67, 22.60 and 14.08. The enantiomeric excess was determined by HPLC using Daicel Chiralpak OJ-H-column, hexane/*i*-PrOH 99:1, flow rate 0.5 mL/min, UV detection at 220 nm,  $t_{minor}$  = 28.980 min,  $t_{major}$  = 32.669 min and 94:6 *er*.

**3-methyl-1-(*p*-tolyl)butan-1-ol (3fa) [96]**

$[a]_D^{20}$  = +35.0 (*c* 0.78, CH<sub>2</sub>Cl<sub>2</sub>). Yield: 88% (78.3 mg) as a yellow solid; m.p. 40–43 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.40–7.04 (m, 4H), 4.67 (dd, *J* = 7.9, 5.5, 1H), 2.33 (s, 3H), 1.93 (s, 1H), 1.76–1.59 (m, 2H), 1.47 (td, *J* = 11.2, 10.0, 5.5, 1H) and 0.93 (dd, *J* = 6.5, 3.1, 6H). <sup>13</sup>C NMR

(100 MHz, CDCl<sub>3</sub>)  $\delta$  142.30, 137.14, 129.16, 125.88, 72.60, 48.28, 24.84, 23.10, 22.36 and 21.13. The enantiomeric excess was determined by HPLC using Daicel Chiralpak AS-H column, hexane/*i*-PrOH 95:5, flow rate 1.0 mL/min, UV detection at 220 nm,  $t_{minor}$  = 4.584 min,  $t_{major}$  = 5.628 min and 93:7 *er*.

*1-(4-chlorophenyl)-3-methylbutan-1-ol (3fe)* [97]

$[a]_D^{20}$  = +37.9 (*c* 0.81, CH<sub>2</sub>Cl<sub>2</sub>). Yield: 82% (81.4 mg) as a light-yellow oil; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.27 (q, *J* = 8.5, 4H), 4.69 (dd, *J* = 8.1, 5.3, 1H), 2.08 (s, 1H), 1.73–1.57 (m, 2H), 1.50–1.38 (m, 1H) and 0.93 (dd, *J* = 6.4, 2.0, 6H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  143.70, 133.06, 128.58, 127.27, 72.09, 48.39, 24.75, 23.09 and 22.22. The enantiomeric excess was determined by HPLC using Daicel Chiralpak AS-H column, hexane/*i*-PrOH 99:1, flow rate 0.5 mL/min, UV detection at 210 nm,  $t_{minor}$  = 24.966 min,  $t_{major}$  = 28.431 min and 95:5 *er*.

*1-(p-tolyl)propan-1-ol (3ga)* [98]

$[a]_D^{20}$  = +37.2 (*c* 0.44, CH<sub>2</sub>Cl<sub>2</sub>). Yield: 88% (66.0 mg) as a light-yellow oil; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.21 (d, *J* = 8.1, 2H), 7.14 (d, *J* = 7.4, 2H), 4.53 (t, *J* = 6.7, 1H), 2.34 (s, 3H), 1.94 (s, 1H), 1.88–1.64 (m, 2H) and 0.90 (t, *J* = 6.4, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  141.67, 137.14, 129.09, 125.96, 75.89, 31.81, 21.12 and 10.20. The enantiomeric excess was determined by HPLC using Daicel Chiralpak AS-H column, hexane/*i*-PrOH 98:2, flow rate 1.0 mL/min, UV detection at 220 nm,  $t_{minor}$  = 10.091 min,  $t_{major}$  = 12.376 min and 94:6 *er*.

*1-(4-chlorophenyl)propan-1-ol (3ge)* [98]

$[a]_D^{20}$  = +32.9 (*c* 0.54, CH<sub>2</sub>Cl<sub>2</sub>). Yield: 83% (70.5 mg) as a light-yellow oil; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.39–7.14 (m, 4H), 4.53 (t, *J* = 6.7, 1H), 2.29 (s, 1H), 1.81–1.61 (m, 2H) and 0.87 (t, *J* = 8.3, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  143.03, 133.05, 128.49, 127.37, 75.24, 31.91 and 9.97. The enantiomeric excess was determined by HPLC using Daicel Chiralpak OD-H column, hexane/*i*-PrOH 98:2, flow rate 1.0 mL/min, UV detection at 210 nm,  $t_{minor}$  = 13.033 min,  $t_{major}$  = 14.609 min and 93:7 *er*.

*2,2-dimethyl-1-(p-tolyl)propan-1-ol (3ha)* [30]

$[a]_D^{20}$  = +30.0 (*c* 0.23, CH<sub>2</sub>Cl<sub>2</sub>). Yield: 45% (40.1 mg) as a light-yellow oil; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  = 7.20 (d, *J* = 8.1, 2H), 7.13 (d, *J* = 8.0, 2H), 4.37 (d, *J* = 2.2, 1H), 2.35 (s, 3H), 1.83 (s, 1H) and 0.92 (s, 9H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  = 139.25, 136.89, 128.27, 127.51, 82.30, 35.62, 25.94 and 21.11. The enantiomeric excess was determined by HPLC using Daicel Chiralpak AS-H column, hexane/*i*-PrOH 95:5, flow rate 1.0 mL/min, UV detection at 220 nm,  $t_{minor}$  = 4.778 min,  $t_{major}$  = 6.400 min and 97:3 *er*.

*(E)-3-phenyl-1-(p-tolyl)prop-2-en-1-ol (3ia)* [99]

$[a]_D^{20}$  = +33.9 (*c* 1.03, CH<sub>2</sub>Cl<sub>2</sub>). Yield: 92% (102.7 mg) as a yellow solid; m.p. 65–68 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.54–6.99 (m, 9H), 6.62 (d, *J* = 15.8, 1H), 6.33 (dd, *J* = 15.8, 6.4, 1H), 5.28 (d, *J* = 6.4, 1H), 2.35 (s, 1H) and 2.32 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  139.98, 137.55, 136.71, 131.79, 130.32, 129.37, 128.62, 127.77, 126.69, 126.43, 74.97 and 21.23. The enantiomeric excess was determined by HPLC using Daicel Chiralpak OD-H column, hexane/*i*-PrOH 90:10, flow rate 1.0 mL/min, UV detection at 254 nm,  $t_{minor}$  = 16.002 min,  $t_{major}$  = 22.736 min and 95:5 *er*.

*4<sup>l</sup>-Methyl-3-phenylpropiophenone (4aa)* [100]

Yellow oil; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.85 (d, *J* = 8.3, 2H), 7.35–7.15 (m, 7H), 3.26 (t, 2H), 3.05 (t, *J* = 7.8, 2H) and 2.39 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  198.98, 143.92, 141.45, 134.36, 129.34, 128.57, 128.49, 128.22, 126.16, 40.42, 30.23 and 21.72.

*Ru-L1*

Yield: 85% (35 mg) as a red solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.36 (t, *J* = 7.9 Hz, 1H), 7.19 (t, *J* = 8.3 Hz, 1H), 6.93 (dd, *J* = 7.6, 1.1 Hz, 1H), 6.88–6.77 (m, 3H), 5.38 (d, *J* = 10.9 Hz, 1H), 4.49 (d, *J* = 10.9 Hz, 1H), 3.96 (s, 3H), 3.77 (s, 3H) and 0.87 (d, *J* = 14.0 Hz, 9H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  161.80, 157.76, 157.71, 136.47, 131.00, 127.61, 125.59, 124.43, 118.32, 110.68, 108.49, 70.53, 63.47, 55.94, 36.42 and 27.25. <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>)  $\delta$  72.32. HRMS-ESI (*m/z*): calculated for C<sub>38</sub>H<sub>47</sub>O<sub>6</sub>Cl<sub>2</sub>RuP<sub>2</sub>, [M+H]: 833.1268, found 833.1254.

**Supplementary Materials:** The following are available online: <https://www.mdpi.com/article/10.3390/molecules27123898/s1>.  $^1\text{H}$ ,  $^{13}\text{C}$  and  $^{31}\text{P}$  NMR spectra, HRMS, and HPLC data of compounds **3aa–3ia**, **4aa** and Ru-L1.

**Author Contributions:** R.L. and L.O. conceived and designed the project and wrote the paper after discussing with R.M. and Y.X. and Y.W. performed the experiments and analyzed the data. All authors have read and agreed to the published version of the manuscript.

**Funding:** This work was funded by the National Natural Science Foundation of China (22161003), Jiangxi provincial department of science and technology (20192BAB203004) and the Fundamental Research Funds for Gannan Medical University (QD201810, TD2021YX05).

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** The data presented in this study and in the Supplementary Materials are available on request from the corresponding author.

**Conflicts of Interest:** The authors declare no conflict of interest.

## References

1. Noyori, R. *Asymmetric Catalysis in Organic Synthesis*; John Wiley & Sons: New York, NY, USA, 1994; pp. 1–635.
2. Jacobsen, E.N.; Pfaltz, A.; Yamamoto, H. *Comprehensive Asymmetric Catalysis*; Springer: Berlin, Germany, 1999; pp. 1–1856.
3. Ojima, I. *Catalytic Asymmetric Synthesis*, 3rd ed.; John Wiley & Sons: Hoboken, NJ, USA, 2000; pp. 1–864.
4. Behr, A.; Vorholt, A.J. *Applied Homogeneous Catalysis with Organometallic Compounds*, 2nd ed.; Cornils, B., Herrmann, W.A., Eds.; Wiley-VCH: Weinheim, Germany, 2002; pp. 1–215.
5. Dhillon, S.; Scott, L.J.; Plosker, G.L. A Review of its use in the management of anxiety disorders. *CNS Drugs* **2006**, *20*, 763–790. [[CrossRef](#)] [[PubMed](#)]
6. Blaser, H.-U.; Federsel, H.-J. *Asymmetric Catalysis in Industrial Scale: Challenges, Approaches and Solutions*, 2nd ed.; Wiley: Weinheim, Germany, 2010; pp. 1–451.
7. Fournier, A.M.; Brown, R.A.; Farnaby, W.; Miyatake-On-dozaal, H.; Clayden, J. Synthesis of (-)-(S, S)-clemastine by invertive N→C aryl migration in a lithiated carbamate. *Org. Lett.* **2010**, *12*, 2222–2225. [[CrossRef](#)] [[PubMed](#)]
8. Collados, J.F.; Solà, R.; Harutyunyan, S.R.; Macia, B. Catalytic synthesis of enantiopure chiral alcohols via addition of grignard reagents to carbonyl compounds. *ACS Catal.* **2016**, *6*, 1952–1970. [[CrossRef](#)]
9. Li, Y.-Y.; Yu, S.-L.; Shen, W.-Y.; Gao, J.-X. Iron, cobalt, and nickel-catalyzed asymmetric transfer hydrogenation and asymmetric hydrogenation of ketones. *Acc. Chem. Res.* **2015**, *48*, 2587–2598. [[CrossRef](#)]
10. Agbossou-Niedercorn, F.; Michon, C. Bifunctional homogeneous catalysts based on first row transition metals in asymmetric hydrogenation. *Coord. Chem. Rev.* **2020**, *425*, 213523. [[CrossRef](#)]
11. Cheemala, M.N.; Gayral, M.; Brown, J.M.; Rossen, K.; Knochel, P. New paracyclophane phosphine for highly enantioselective ruthenium-catalyzed hydrogenation of prochiral ketones. *Synthesis* **2007**, *24*, 3877–3885. [[CrossRef](#)]
12. Li, Y.; Zhou, Y.; Shi, Q.; Ding, K.; Noyori, R.; Sandoval, C.A. An Efficient diphosphine/hybrid-amine combination for ruthenium(II)-catalyzed asymmetric hydrogenation of aryl ketones. *Adv. Synth. Catal.* **2011**, *353*, 495–500. [[CrossRef](#)]
13. Zhu, Y.; Zhou, J.; Li, J.; Xu, K.; Ye, J.; Lu, Y.; Liu, D.; Zhang, W. Kinetic resolution of azaflavanones via a RuPHOX-Ru catalyzed asymmetric hydrogenation. *Org. Chem. Front.* **2021**, *8*, 6609–6615. [[CrossRef](#)]
14. Xiao, J.; Li, X.; Blacker, J.; Houson, I.; Wu, X. An efficient Ir (III) catalyst for the asymmetric transfer hydrogenation of ketones in neat water. *Synlett* **2006**, *2006*, 1155–1160. [[CrossRef](#)]
15. Wu, X.; Li, X.; Zanotti-Gerosa, A.; Pettman, A.; Liu, J.; Mills, A.J.; Xiao, J. Rh III- and Ir III-catalyzed asymmetric transfer hydrogenation of ketones in water. *Chem. Eur. J.* **2008**, *14*, 2209–2222. [[CrossRef](#)]
16. Zirakzadeh, A.; Schuecker, R.; Gorgas, N.; Mereiter, K.; Spindler, F.; Weissensteiner, W. Ruthenium complexes of phosphino-substituted ferrocenyloxazolines in the asymmetric hydrogenation and transfer hydrogenation of ketones: A comparison. *Organometallics* **2012**, *31*, 4241–4250. [[CrossRef](#)]
17. Wang, Y.; Franzen, R. Synthesis of 2-aryl-substituted chromans by intramolecular C–O bond formation. *Synlett* **2012**, *6*, 925–929.
18. Tang, S.; Jin, R.; Zhang, H.; Yao, H.; Zhuang, J.; Liu, G.; Li, H. Recoverable organorhodium-functionalized polyhedral oligomeric silsesquioxane: A bifunctional heterogeneous catalyst for asymmetric transfer hydrogenation of aromatic ketones in aqueous medium. *Chem. Commun.* **2012**, *48*, 6286–6288. [[CrossRef](#)] [[PubMed](#)]
19. Shoola, C.O.; DelMastro, T.; Wu, R.; Sowa, J.R.J. Asymmetric transfer hydrogenation of secondary allylic alcohols. *Eur. J. Org. Chem.* **2015**, *2015*, 1670–1673. [[CrossRef](#)]
20. Hejazifar, M.; Pálvölgyi, Á.M.; Bitai, J.; Lanaridi, O.; Bica-Schröder, K. Asymmetric transfer hydrogenation in thermomorphic microemulsions based on ionic liquids. *Org. Process Res. Dev.* **2019**, *23*, 1841–1851. [[CrossRef](#)]

21. Ramasamy, B.; Gangwar, M.K.; Ghosh, P. Asymmetric transfer hydrogenation of  $\alpha,\beta$ -unsaturated carbonyl compounds to saturated alcohols as catalyzed by iridium complexes of tricyclic bioazoline-fused imidazole-derived *N*-heterocyclic carbene ligands. *ChemistrySelect* **2019**, *4*, 357–365. [[CrossRef](#)]
22. Bolm, C.; Muniz, K. Catalytic enantioselective aryl transfer: Asymmetric addition of diphenylzinc to aldehydes. *Chem. Commun.* **1999**, *14*, 1295–1296. [[CrossRef](#)]
23. Chaumont-Olive, P.; Rouen, M.; Barozzino-Consiglio, G.; Ben Abdeladhim, A.; Maddaluno, J.; Harrison-Marchand, A. Chiral lithium amido aryl zincates: Simple and efficient chemo- and enantio-selective aryl transfer reagents. *Angew. Chem. Int. Ed.* **2019**, *58*, 3193–3197. [[CrossRef](#)]
24. Liu, Y.; Da, C.S.; Yu, S.L.; Yin, X.G.; Wang, J.R.; Fan, X.Y.; Li, W.P.; Wang, R. Catalytic highly enantioselective alkylation of aldehydes with deactivated grignard reagents and synthesis of bioactive intermediate secondary arylpropanols. *J. Org. Chem.* **2010**, *75*, 6869–6878. [[CrossRef](#)]
25. OH, O. Lithiated primary alkyl carbamates for the homologation of boronic esters. *Org. Synth.* **2011**, *88*, 247–259.
26. Larouche-Gauthier, R.; Fletcher, C.J.; Couto, I.; Aggarwal, V.K. Use of Alkyl 2,4,6-triisopropylbenzoates in the asymmetric homologation of challenging boronic esters. *Chem. Commun.* **2011**, *47*, 12592–12594. [[CrossRef](#)] [[PubMed](#)]
27. Barsamian, A.L.; Wu, Z.; Blakemore, P.R. Enantioselective synthesis of alpha-phenyl- and alpha-(dimethylphenylsilyl)alkylboronic esters by ligand mediated stereo inductive reagent-controlled homologation using configurationally labile carbenoids. *Org. Biomol. Chem.* **2015**, *13*, 3781–3786. [[CrossRef](#)] [[PubMed](#)]
28. Binanzer, M.; Fang, G.Y.; Aggarwal, V.K. Asymmetric synthesis of allylsilanes by the borylation of lithiated carbamates: Formal total synthesis of (-)-decastrictine D. *Angew. Chem. Int. Ed.* **2010**, *49*, 4264–4268. [[CrossRef](#)] [[PubMed](#)]
29. Nishide, K.; Shigeta, Y.; Obata, K.; Node, M. Asymmetric 1,7-hydride shift: The highly asymmetric reduction of  $\alpha, \beta$ -unsaturated ketones to secondary alcohols via a novel tandem michael addition Meerwein-Ponndorf-Verley reduction. *J. Am. Chem. Soc.* **1996**, *118*, 13103–13104. [[CrossRef](#)]
30. Yamamoto, Y.; Shirai, T.; Watanabe, M.; Kurihara, K.; Miyaura, N. Ru/Me-BIPAM-catalyzed asymmetric addition of arylboronic acids to aliphatic aldehydes and  $\alpha$ -ketoesters. *Molecules* **2011**, *16*, 5020–5034. [[CrossRef](#)]
31. Abadie, M.-A.; MacIntyre, K.; Boulho, C.; Hoggan, P.; Capet, F.; Agbossou-Niedercorn, F.; Michon, C. Development of chiral  $C_2$ -symmetric *N*-heterocyclic carbene Rh(I) catalysts through control of their steric properties. *Organometallics* **2019**, *38*, 536–543. [[CrossRef](#)]
32. Margalef, J.; Slagbrand, T.; Tinnis, F.; Adolfsson, H.; Dieguez, M.; Pamies, O. Third-generation amino acid furanoside-based ligands from d-mannose for the asymmetric transfer hydrogenation of ketones: Catalysts with an exceptionally wide substrate scope. *Adv. Synth. Catal.* **2016**, *358*, 4006–4018. [[CrossRef](#)]
33. Wang, K.; Zhang, L.; Tang, W.; Sun, H.; Xue, D.; Lei, M.; Xiao, J.; Wang, C. Asymmetric guerbet reaction to access chiral alcohols. *Angew. Chem. Int. Ed.* **2020**, *132*, 11505–11512. [[CrossRef](#)]
34. Ng, T.W.; Liao, G.; Lau, K.K.; Pan, H.J.; Zhao, Y. Room-temperature guerbet reaction with unprecedented catalytic efficiency and enantioselectivity. *Angew. Chem. Int. Ed.* **2020**, *59*, 11384–11389. [[CrossRef](#)]
35. Wang, G.; Gan, Y.; Liu, Y. Nickel-catalyzed direct coupling of allylic alcohols with organoboron reagents. *Chin. J. Chem.* **2018**, *36*, 916–920. [[CrossRef](#)]
36. West, M.J.; Fyfe, J.W.; Vantourout, J.C.; Watson, A.J. Mechanistic development and recent applications of the Chan-Lam amination. *Chem. Rev.* **2019**, *119*, 12491–12523. [[CrossRef](#)] [[PubMed](#)]
37. Corpas, J.; Mauleón, P.; Arrayás, R.G.; Carretero, J.C. Transition-metal-catalyzed functionalization of alkynes with organoboron reagents: New trends, mechanistic insights, and applications. *ACS Catal.* **2021**, *11*, 7513–7551. [[CrossRef](#)]
38. Dimitrijevic, E.; Taylor, M.S. Organoboron acids and their derivatives as catalysts for organic synthesis. *ACS Catal.* **2013**, *3*, 945–962. [[CrossRef](#)]
39. Sakai, M.; Ueda, M.; Miyaura, N. Rhodium-catalyzed addition of organoboronic acids to aldehydes. *Angew. Chem. Int. Ed.* **1998**, *37*, 3279–3281. [[CrossRef](#)]
40. Duan, H.-F.; Xie, J.-H.; Shi, W.-J.; Zhang, Q.; Zhou, Q.-L. Enantioselective rhodium-catalyzed addition of arylboronic acids to aldehydes using chiral spiro monophosphite ligands. *Org. Lett.* **2006**, *8*, 1479–1481. [[CrossRef](#)]
41. Noel, T.; Vandyck, K.; Van der Eycken, J. Some new  $C_2$ -symmetric bicyclo [2.2.1] heptadiene ligands: Synthesis and catalytic activity in rhodium(I)-catalyzed asymmetric 1,4- and 1,2-Additions. *Tetrahedron* **2007**, *63*, 12961–12967. [[CrossRef](#)]
42. Nishimura, T.; Kumamoto, H.; Nagaosa, M.; Hayashi, T. The concise synthesis of chiral tfb ligands and their application to the Rhodium-catalyzed asymmetric arylation of aldehydes. *Chem. Commun.* **2009**, *38*, 5713–5715. [[CrossRef](#)]
43. Morikawa, S.; Michigami, K.; Amii, H. Novel axially chiral phosphine ligand with a fluoro alcohol moiety for Rh-catalyzed asymmetric arylation of aromatic aldehydes. *Org. Lett.* **2010**, *12*, 2520–2523. [[CrossRef](#)]
44. Duan, W.; Ma, Y.; Qu, B.; Zhao, L.; Chen, J.; Song, C. Synthesis of new alkoxy/sulfonate-substituted carbene precursors derived from [2.2] paracyclophane and their application in the asymmetric arylation of aldehydes. *Tetrahedron Asymmetry* **2012**, *23*, 1369–1375. [[CrossRef](#)]
45. Duan, W.; Ma, Y.; He, F.; Zhao, L.; Chen, J.; Song, C. Synthesis of novel planar chiral Ag and Rh *N*-heterocyclic carbene complexes derived from [2.2] paracyclophane and their application in ultrasound assisted asymmetric addition reactions of organoboronic acids to aldehydes. *Tetrahedron Asymmetry* **2013**, *24*, 241–248. [[CrossRef](#)]

46. Chen, J.; Yang, S.; Chen, Z.; Song, C.; Ma, Y. Synthesis of novel macrocyclic planar chiral carbene-Ag complexes derived from [2.2] paracyclophane for Rh-catalyzed asymmetric 1, 2-additions of arylboronic acids to aromatic aldehydes. *Tetrahedron Asymmetry* **2015**, *26*, 288–295. [[CrossRef](#)]
47. He, W.-P.; Zhou, B.-H.; Zhou, Y.-L.; Li, X.-R.; Fan, L.-M.; Shou, H.-W.; Li, J. Synthesis of new benzimidazolium salts and their application in the asymmetric arylation of aldehydes. *Tetrahedron Lett.* **2016**, *57*, 3152–3155. [[CrossRef](#)]
48. Kamikawa, K.; Tseng, Y.-Y.; Jian, J.-H.; Takahashi, T.; Ogasawara, M. Planar-chiral phosphine-olefin ligands exploiting a (cyclopentadienyl) manganese (I) scaffold to achieve high robustness and high enantioselectivity. *J. Am. Chem. Soc.* **2017**, *139*, 1545–1553. [[CrossRef](#)] [[PubMed](#)]
49. Lu, Z.; Zhang, H.; Yang, Z.; Ding, N.; Meng, L.; Wang, J. Asymmetric hydrophosphination of heterobicyclic alkenes: Facile access to phosphine ligands for asymmetric catalysis. *ACS Catal.* **2019**, *9*, 1457–1463. [[CrossRef](#)]
50. Arao, T.; Kondo, K.; Aoyama, T. Nickel-catalyzed 1, 2-addition of arylboroxines to aromatic aldehydes. *Tetrahedron Lett.* **2007**, *48*, 4115–4117. [[CrossRef](#)]
51. Karthikeyan, J.; Jeganmohan, M.; Cheng, C.H. Cobalt-catalyzed addition reaction of organoboronic acids with aldehydes: Highly enantioselective synthesis of diarylmethanols. *Chem. Eur. J.* **2010**, *16*, 8989–8992. [[CrossRef](#)]
52. Suzuma, Y.; Hayashi, S.; Yamamoto, T.; Oe, Y.; Ohta, T.; Ito, Y. Asymmetric 1, 4-addition of organoboronic acids to  $\alpha$ ,  $\beta$ -unsaturated ketones and 1, 2-addition to aldehydes catalyzed by a palladium complex with a ferrocene-based phosphine ligand. *Tetrahedron Asymmetry* **2009**, *20*, 2751–2758. [[CrossRef](#)]
53. Loxq, P.; Debono, N.; Gülcemal, S.; Daran, J.-C.; Manoury, E.; Poli, R.; Çetinkaya, B.; Labande, A. Palladium(II) complexes with planar chiral ferrocenyl phosphane-(benz)imidazol-2-ylidene ligands. *New J. Chem.* **2014**, *38*, 338–347. [[CrossRef](#)]
54. (c) Zhang, R.; Xu, Q.; Zhang, X.; Zhang, T.; Shi, M. Axially chiral C<sub>2</sub>-symmetric N-heterocyclic carbene (NHC) palladium complexes-catalyzed asymmetric arylation of aldehydes with arylboronic acids. *Tetrahedron Asymmetry* **2010**, *21*, 1928–1935. [[CrossRef](#)]
55. Shintani, R.; Inoue, M.; Hayashi, T. Rhodium-catalyzed asymmetric addition of aryl- and alkenylboronic acids to isatins. *Angew. Chem. Int. Ed.* **2006**, *118*, 3431–3434. [[CrossRef](#)]
56. Toullec, P.Y.; Jagt, R.B.; de Vries, J.G.; Feringa, B.L.; Minnaard, A.J. Rhodium-catalyzed addition of arylboronic acids to isatins: An entry to diversity in 3-aryl-3-hydroxyoxindoles. *Org. Lett.* **2006**, *8*, 2715–2718. [[CrossRef](#)] [[PubMed](#)]
57. Zhuang, Y.; He, Y.; Zhou, Z.; Xia, W.; Cheng, C.; Wang, M.; Chen, B.; Zhou, Z.; Pang, J.; Qiu, L. Synthesis of a class of chiral-bridged phosphoramidite ligands and their applications in the first iridium-catalyzed asymmetric addition of arylboronic acids to isatins. *J. Org. Chem.* **2015**, *80*, 6968–6975. [[CrossRef](#)] [[PubMed](#)]
58. Marques, C.S.; Burke, A.J. Enantioselective rhodium(I)-catalyzed additions of arylboronic acids to N-1,2,3-triazole-isatin derivatives: Accessing N-(1,2,3-triazolmethyl)-3-hydroxy-3-aryloxindoles. *ChemCatChem* **2016**, *8*, 3518–3526. [[CrossRef](#)]
59. Duan, H.F.; Xie, J.H.; Qiao, X.C.; Wang, L.X.; Zhou, Q.L. Enantioselective rhodium-catalyzed addition of arylboronic acids to  $\alpha$ -ketoesters. *Angew. Chem. Int. Ed.* **2008**, *120*, 4423–4425. [[CrossRef](#)]
60. Cai, F.; Pu, X.; Qi, X.; Lynch, V.; Radha, A.; Ready, J.M. Chiral allene-containing phosphines in asymmetric catalysis. *J. Am. Chem. Soc.* **2011**, *133*, 18066–18069. [[CrossRef](#)]
61. Zhu, T.S.; Jin, S.S.; Xu, M.H. Rhodium-catalyzed, highly enantioselective 1, 2-addition of aryl boronic acids to  $\alpha$ -ketoesters and  $\alpha$ -diketones using simple, chiral sulfur-olefin ligands. *Angew. Chem. Int. Ed.* **2012**, *124*, 804–807. [[CrossRef](#)]
62. Chang, C.A.; Uang, T.Y.; Jian, J.H.; Zhou, M.Y.; Chen, M.L.; Kuo, T.S.; Wu, P.Y.; Wu, H.L. Efficient and enantioselective rhodium (I)-catalyzed arylation of  $\alpha$ -ketoesters: Synthesis of (S)-flutriafol. *Adv. Synth. Catal.* **2018**, *360*, 3381–3390. [[CrossRef](#)]
63. Bartlett, S.L.; Keiter, K.M.; Johnson, J.S. Synthesis of complex tertiary glycolates by entioconvergent arylation of stereochemically labile  $\alpha$ -Keto Esters. *J. Am. Chem. Soc.* **2017**, *139*, 3911–3916. [[CrossRef](#)]
64. Feng, X.; Nie, Y.; Yang, J.; Du, H. Rh(I)-Catalyzed asymmetric 1, 2-addition to  $\alpha$ -diketones with chiral sulfur-alkene hybrid ligands. *Org. Lett.* **2012**, *14*, 624–627. [[CrossRef](#)]
65. Wen, Q.; Zhang, L.; Xiong, J.; Zeng, Q.L. A new type of chiral cyclic sulfinamide-olefin ligands for rhodium-catalyzed asymmetric addition. *Eur. J. Org. Chem.* **2016**, *2016*, 5360–5364. [[CrossRef](#)]
66. Zhang, Z.-F.; Zhu, D.-X.; Chen, W.-W.; Xu, B.; Xu, M.-H. Enantioselective synthesis of gem-diaryl benzofuran-3(2H)-ones via one-pot asymmetric rhodium/palladium relay catalysis. *Org. Lett.* **2017**, *19*, 2726–2729. [[CrossRef](#)] [[PubMed](#)]
67. Martina, S.L.; Jagt, R.B.; de Vries, J.G.; Feringa, B.L.; Minnaard, A.J. Enantioselective rhodium-catalyzed addition of arylboronic acids to trifluoromethyl ketones. *Chem. Commun.* **2006**, *39*, 4093–4095. [[CrossRef](#)] [[PubMed](#)]
68. Jumde, V.R.; Facchetti, S.; Iuliano, A. A chiral Rh-phosphite complex displaying high activity in the enantioselective Rh-catalyzed addition of arylboronic acids to carbonyl compounds: When and why atropos is better than tropos. *Tetrahedron Asymmetry* **2010**, *21*, 2775–2781. [[CrossRef](#)]
69. Luo, R.; Li, K.; Hu, Y.; Tang, W. Enantioselective rhodium-catalyzed addition of arylboronic acids to trifluoromethyl ketones. *Adv. Synth. Catal.* **2013**, *355*, 1297–1302. [[CrossRef](#)]
70. Korenaga, T.; Ko, A.; Uotani, K.; Tanaka, Y.; Sakai, T. Synthesis and application of 2, 6-Bis (trifluoromethyl)-4-pyridyl phosphanes: The most electron-poor aryl phosphanes with moderate bulkiness. *Angew. Chem. Int. Ed.* **2011**, *50*, 10703–10707. [[CrossRef](#)]
71. Liao, Y.-X.; Xing, C.-H.; Hu, Q.-S. Rhodium (I)/Diene-catalyzed addition reactions of arylborons with ketones. *Org. Lett.* **2012**, *14*, 1544–1547. [[CrossRef](#)]



72. Huang, L.; Zhu, J.; Jiao, G.; Wang, Z.; Yu, X.; Deng, W.P.; Tang, W. Highly enantioselective rhodium-catalyzed addition of arylboroxines to simple aryl ketones: Efficient synthesis of escitalopram. *Angew. Chem. Int. Ed.* **2016**, *55*, 4527–4531. [[CrossRef](#)]
73. Richard, B.; áde Vries, J.G. Rhodium/Phosphoramidite-Catalyzed asymmetric arylation of aldehydes with arylboronic acids. *Org. Biomol. Chem.* **2006**, *4*, 773–775.
74. Ma, Q.; Ma, Y.; Liu, X.; Duan, W.; Qu, B.; Song, C. Planar chiral imidazolium salts based on [2.2] paracyclophane in the asymmetric rhodium-catalyzed 1, 2-addition of arylboronic Acids to Aldehydes. *Tetrahedron Asymmetry* **2010**, *21*, 292–298. [[CrossRef](#)]
75. Wang, D.; Ma, Y.; He, F.; Duan, W.; Zhao, L.; Song, C. Synthesis of planar chiral [2.2] paracyclophanylImidazo [1, 5-a] pyridinium salts for the rhodium-catalyzed asymmetric arylation. *Synth. Commun.* **2013**, *43*, 810–825. [[CrossRef](#)]
76. Wu, T.; Zhou, Q.; Tang, W. Enantioselective  $\alpha$ -carbonylative arylation for facile construction of chiral spirocyclic  $\beta$ ,  $\beta'$ -diketones. *Angew. Chem. Int. Ed.* **2021**, *60*, 9978–9983. [[CrossRef](#)] [[PubMed](#)]
77. Tian, D.; Xu, R.; Zhu, J.; Huang, J.; Dong, W.; Claverie, J.; Tang, W. Asymmetric hydroesterification of diarylmethyl carbinols. *Angew. Chem. Int. Ed.* **2021**, *60*, 6305–6309. [[CrossRef](#)] [[PubMed](#)]
78. Li, K.; Nie, M.; Tang, W. Synthesis of  $\alpha$ -tertiary allylsilanes by palladium-catalyzed hydrosilylation of 1, 1-disubstituted allenes. *Green Synth. Catal.* **2020**, *1*, 171–174. [[CrossRef](#)]
79. Xu, R.H.; Yang, H.; Tang, W. Efficient synthesis of chiral drugs facilitated by P-chiral phosphorus ligands. *Chin. J. Org. Chem.* **2020**, *40*, 1409–1422. [[CrossRef](#)]
80. Wu, T.; Xu, G.; Tang, W. P-Chiral Phosphorus Ligands for Cross-Coupling and Asymmetric Hydrogenation Reactions. *Aldrichimica Acta* **2020**, *53*, 27–35.
81. Xu, G.; Senanayake, C.H.; Tang, W. P-Chiral phosphorus ligands based on a 2,3-dihydrobenzo [*d*] [1,3] oxaphosphole motif for asymmetric catalysis. *Acc. Chem. Res.* **2019**, *52*, 1101–1112. [[CrossRef](#)]
82. Yang, H.; Tang, W. Efficient enantioselective syntheses of chiral natural products facilitated by ligand design. *Chem. Rec.* **2019**, *19*, 1–19.
83. Li, K.; Hu, N.; Luo, R.; Yuan, W.; Tang, W. A chiral ruthenium-monophosphine catalyst for asymmetric addition of arylboronic acids to aryl aldehydes. *J. Org. Chem.* **2013**, *78*, 6350–6355. [[CrossRef](#)]
84. Barkow, A.; Pilotek, S.; Grützmacher, H.-F. Ortho effects: A mechanistic study. *Eur. Mass Spectrom.* **1995**, *6*, 525–537. [[CrossRef](#)]
85. Kaur, M.; Reshi, N.U.D.; Patra, K.; Bhattacharya, A.; Kunnikuruvan, S.; Bera, J.K. A proton-responsive pyridyl (benzamide)-functionalized NHC ligand on Ir complex for alkylation of ketones and secondary alcohols. *Chem. Eur. J.* **2021**, *27*, 10732–10748. [[CrossRef](#)]
86. El-Sepelgy, O.; Matador, E.; Brzozowska, A.; Rueping, M. C-alkylation of secondary alcohols by primary alcohols through manganese-catalyzed double hydrogen autotransfer. *ChemSusChem* **2019**, *12*, 3099–3102. [[CrossRef](#)] [[PubMed](#)]
87. Wang, D.; Guo, X.Q.; Wang, C.X.; Wang, Y.N.; Zhong, R.; Zhu, X.H.; Cai, L.H.; Gao, Z.W.; Hou, X.F. An efficient and recyclable catalyst for *N*-alkylation of amines and  $\beta$ -alkylation of secondary alcohols with primary alcohols: SBA-15 supported *N*-heterocyclic carbene iridium complex. *Adv. Synth. Catal.* **2013**, *3*, 1117–1125. [[CrossRef](#)]
88. Liu, J.; Li, W.; Li, Y.; Liu, Y.; Ke, Z. Selective C-alkylation between alcohols catalyzed by *N*-heterocyclic carbene molybdenum. *Chem. Asian J.* **2021**, *16*, 3124–3128. [[CrossRef](#)] [[PubMed](#)]
89. Liu, T.; Wang, L.; Wu, K.; Yu, Z. Manganese-catalyzed  $\beta$ -alkylation of secondary alcohols with primary alcohols under phosphine-free conditions. *ACS Catal.* **2018**, *8*, 7201–7207. [[CrossRef](#)]
90. Kaya, U.; Tran, U.P.; Enders, D.; Ho, J.; Nguyen, T.V. *N*-Heterocyclic olefin catalyzed silylation and hydrosilylation reactions of hydroxyl and carbonyl compounds. *Org. Lett.* **2017**, *19*, 1398–1401. [[CrossRef](#)]
91. Xu, Q.; Chen, J.; Tian, H.; Yuan, X.; Li, S.; Zhou, C.; Liu, J. Catalyst-free dehydrative  $\alpha$ -alkylation of ketones with alcohols: Green and selective autocatalyzed synthesis of alcohols and ketones. *Angew. Chem. Int. Ed.* **2014**, *126*, 229–233. [[CrossRef](#)]
92. Babu, R.; Subramanian, M.; Midya, S.P.; Balaraman, E. Nickel-catalyzed guerbet type reaction: C-alkylation of secondary alcohols via double (de) hydrogenation. *Org. Lett.* **2021**, *23*, 3320–3325. [[CrossRef](#)]
93. Kabalka, G.W.; Wu, Z.; Trotman, S.E.; Gao, X. Alkylation of aromatic aldehydes with boron halide derivatives. *Org. Lett.* **2000**, *2*, 255–256. [[CrossRef](#)]
94. Shailaja, J.; Kaanumalle, L.S.; Sivasubramanian, K.; Natarajan, A.; Ponchot, K.J.; Pradhan, A.; Ramamurthy, V. Asymmetric induction during electron transfer mediated photoreduction of carbonyl compounds: Role of zeolites. *Org. Biomol. Chem.* **2006**, *4*, 1561–1571. [[CrossRef](#)]
95. Hirao, Y.; Katayama, Y.; Mitsunuma, H.; Kanai, M. Chromium-catalyzed linear-selective alkylation of aldehydes with alkenes. *Org. Lett.* **2020**, *22*, 8584–8588. [[CrossRef](#)]
96. Liao, Y.-X.; Xing, C.-H.; He, P.; Hu, Q.-S. Orthoplatinated Triarylphosphite as a highly efficient catalyst for addition reactions of arylboronic acids with aldehydes: Low catalyst loading catalysis and a new tandem reaction sequence. *Org. Lett.* **2008**, *10*, 2509–2512. [[CrossRef](#)] [[PubMed](#)]
97. Asada, M.; Iwahashi, M.; Obitsu, T.; Kinoshita, A.; Nakai, Y.; Onoda, T.; Nagase, T.; Tanaka, M.; Yamaura, Y.; Takizawa, H. 3-(2-Aminocarbonylphenyl) propanoic acid analogs as potent and selective EP3receptor antagonists. Part 2: Optimization of the side chains to improve in vitro and in vivo potencies. *Bioorgan. Med. Chem.* **2010**, *18*, 1641–1658. [[CrossRef](#)] [[PubMed](#)]
98. Irrgang, T.; Friedrich, D.; Kempe, R. Highly enantioselective amido iridium catalysts for the hydrogenation of simple ketones. *Angew. Chem. Int. Ed.* **2011**, *50*, 2183–2186. [[CrossRef](#)] [[PubMed](#)]

99. Keinan, E.; Peretz, M. Organotin nucleophiles. Palladium-catalyzed allylic propargylation with allenylstannane. *J. Org. Chem.* **1983**, *48*, 5302–5309. [[CrossRef](#)]
100. Ma, Z.; Wang, Y. Dirhodium(ii)/P(*t*-Bu)<sub>3</sub> catalyzed tandem reaction of alpha, beta-unsaturated aldehydes with arylboronic acids. *Org. Biomol. Chem.* **2018**, *16*, 7470–7476. [[CrossRef](#)] [[PubMed](#)]